Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 2/20 | 0.50 |
| ▸ | GHSR | Q92847 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.49 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608854 | 1.00 | PBK (0.50) | PBKGHSRCYP1A2CHEK1CDK2AP1 | |
| SCHEMBL3603356 | 0.93 | DGAT1 (0.48) | PBKGHSRCYP1A2CHEK1CDK2AP1 | |
| SCHEMBL3603353 | 0.93 | DGAT1 (0.48) | PBKGHSRCYP1A2CHEK1CDK2AP1 | |
| SCHEMBL3320269 | 0.86 | MLLT1 (0.54) | GHSRCYP1A2MLLT1PARP1CHRNA1 | |
| SCHEMBL3607328 | 0.86 | MLLT1 (0.54) | GHSRCYP1A2MLLT1PARP1CHRNA1 | |
| SCHEMBL3320273 | 0.86 | MLLT1 (0.54) | GHSRCYP1A2MLLT1PARP1CHRNA1 | |
| SCHEMBL3612490 | 0.83 | DRD4 (0.50) | PBKGHSRCYP1A2MLLT1PARP1 | |
| SCHEMBL3612493 | 0.83 | DRD4 (0.50) | PBKGHSRCYP1A2MLLT1PARP1 | |
| SCHEMBL3605105 | 0.83 | ALOX15 (0.54) | PBKCHEK1CDK2AP1MLLT1PARP1 | |
| SCHEMBL3605108 | 0.83 | ALOX15 (0.54) | PBKCHEK1CDK2AP1MLLT1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | PBK 2463/4885GHSR 2639/4885CYP1A2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.